English

ThisiscontentfromElsevier'sDrugInformation

Olaparib

Learn more about Elsevier's Drug Information today! Get the drug data and decision support you need, including TRUE Daily Updates™ including every day including weekends and holidays.

Nov.16.2023

Olaparib

Indications/Dosage

Labeled

  • breast cancer
  • ovarian cancer
  • pancreatic cancer
  • prostate cancer

Off-Label

    † Off-label indication

    For the treatment of ovarian cancer

    for the first-line maintenance treatment of deleterious or suspected deleterious germline or somatic BRCA mutated (gBRCAm or sBRCAm) advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are in a complete or partial response to first-line platinum-based chemotherapy, as monotherapy

    Oral dosage

    Adults

    300 mg PO twice daily until disease progression, unacceptable toxicity, or completion of 2 years of treatment. Patients with a complete response (no radiological evidence of disease) at 2 years should stop treatment. Patients with evidence of disease at 2 years can continue treatment with olaparib if the treating healthcare provider feels the patient can derive further benefit. Coadministration of certain drugs may need to be avoided or dosage adjustments may be necessary; review drug interactions. In a multicenter, randomized, double-blind, phase 3 clinical trial, maintenance therapy with olaparib significantly improved PFS (not reached vs.13.8 months) and time to first subsequent treatment (51.8 months vs. 15.1 months) compared with placebo in patients with newly diagnosed gBRCAm advanced or high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer in patients who were in a complete or partial response to platinum-based chemotherapy (SOLO1 trial).[63696] [58662]

    for the first-line maintenance treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are in a complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a deleterious or suspected deleterious BRCA mutation and/or genomic instability, in combination with bevacizumab

    Oral dosage

    Adults

    300 mg PO twice daily until disease progression, unacceptable toxicity, or completion of 2 years of treatment, in combination with bevacizumab (15 mg/kg IV every 3 weeks for 15 months total, including the period given with chemotherapy and given with maintenance). Patients with a complete response (no radiological evidence of disease) at 2 years should stop treatment with olaparib. Patients with evidence of disease at 2 years can continue treatment with olaparib if the treating healthcare provider feels the patient can derive further benefit. Coadministration of certain drugs may need to be avoided or dosage adjustments may be necessary; review drug interactions. Maintenance therapy with olaparib plus bevacizumab significantly improved the primary outcome of median progression-free survival compared with patients receiving bevacizumab plus placebo in HRD-positive patients with advanced high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer following first-line platinum-based chemotherapy and bevacizumab in a multicenter, randomized, double-blind clinical trial (PAOLA-1) (37.2 months vs. 17.7 months); the median overall survival rate was also significantly improved in the olaparib/bevacizumab arm (75.2 months vs. 57.3 months).[58662] [69881]

    for the maintenance treatment of deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAm or sBRCAm) recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are in a complete or partial response to platinum-based chemotherapy, as monotherapy

    Oral dosage

    Adults

    300 mg PO twice daily until disease progression or unacceptable toxicity. Coadministration of certain drugs may need to be avoided or dosage adjustments may be necessary; review drug interactions. Maintenance treatment with olaparib (n = 196) significantly improved the primary endpoint of median progression-free survival (PFS) compared with placebo (n = 99) in a randomized, double-blind clinical trial of patients with gBRCAm ovarian, fallopian tube, or primary peritoneal cancer who had obtained either a complete or partial response to platinum-based chemotherapy (19.1 months vs. 5.5 months) (SOLO2 trial). Approximately 44% of olaparib patients and 37% of placebo patients in this trial had received 3 or more lines of platinum-based treatment. In long-term follow-up, 24% of patients were treated with olaparib for 2 years and 11% received treatment for over 6 years. Olaparib improved overall survival compared with placebo (51.7 months vs. 38.8 months) irrespective of BRCA 1/2 mutation status but did not meet the predefined threshold for statistical significance.[58662] [65864] [66532]

    for the treatment of deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer in patients who have failed 3 or more prior courses of chemotherapy, as monotherapy†

    Oral dosage

    Adults

    Dosage not available.

    For the treatment of breast cancer

    for the adjuvant treatment of of germline BRCA-mutated (gBRCAm) HER2-negative high risk early breast cancer in patients who have been treated with neoadjuvant or adjuvant chemotherapy

    Oral dosage

    Adults

    300 mg orally twice daily for a total of 1 year, or until disease progression or unacceptable toxicity if occurring before 1 year. Patients with hormone receptor-positive breast cancer should continue to receive concurrent endocrine therapy according to current clinical practice guidelines. Coadministration of certain drugs may need to be avoided or dosage adjustments may be necessary; review drug interactions. In a multicenter, randomized, double-blind, phase 3 clinical trial (OlympiA), patients with gBRCAm HER2-negative high risk early breast cancer who had completed definitive local treatment and neoadjuvant or adjuvant chemotherapy were randomized to receive 1 year of olaparib or placebo. Treatment with olaparib significantly improved 3-year invasive disease-free survival (85.9% vs. 77.1%) and 3-year distant disease-free survival (87.5% vs. 804%) compared with placebo. Olaparib was also associated with fewer deaths than placebo, although at the interim analysis this difference was not statistically significant.[58662] [67934]

    for the treatment of HER2-negative, deleterious or suspected deleterious germline BRCA mutated (gBRCAm) metastatic breast cancer in patients who have been previously treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting

    Oral dosage

    Adults

    300 mg orally twice daily until disease progression or unacceptable toxicity. Coadministration of certain drugs may need to be avoided or dosage adjustments may be necessary; review drug interactions. Olaparib monotherapy significantly improved the primary endpoint of progression-free survival (PFS) compared with physician's choice of single-agent chemotherapy in patients with HER2-negative, gBRCAm metastatic breast cancer in a phase 3 clinical trial; subgroup analysis indicates patients with triple-negative breast cancer or BRCA1 mutations confer significant benefit.[62322] [58662] [67934]

    For the treatment of pancreatic cancer

    NOTE: Olaparib has been designated by the FDA as an orphan drug for the treatment of pancreatic cancer.

    for the first-line maintenance treatment of deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma in patients who have not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen

    Oral dosage

    Adults

    300 mg PO twice daily until disease progression or unacceptable toxicity. Coadministration of certain drugs may need to be avoided or dosage adjustments may be necessary; review drug interactions. In a multicenter, randomized clinical trial, maintenance therapy with olaparib after a lack of disease progression on at least 16 weeks of first-line platinum-based chemotherapy significantly improved median progression-free survival compared with placebo (7.4 months vs. 3.8 months) in patients with deleterious or suspected deleterious gBRCA-mutated metastatic pancreatic cancer. The objective response rate was 23% (complete response [CR], 2.6%) in the olaparib arm compared with 12% (CR, 0%) in patients who received placebo, for a median duration of 25 months versus 4 months, respectively.[58662] [64904] In the final analysis, median overall survival was 19 months in patients who received olaparib and 19.2 months in patients who received placebo.[58662] [67346]

    For the treatment of prostate cancer

    for the treatment of deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), after progression on enzalutamide or abiraterone

    Oral dosage

    Adults

    300 mg PO twice daily until disease progression or unacceptable toxicity. Patients should concurrently receive treatment with a gonadotropin-releasing hormone (GnRH) analog or have had a bilateral orchiectomy. Coadministration of certain drugs may need to be avoided or dosage adjustments may be necessary; review drug interactions. In a multicenter, randomized, open-label clinical trial (the PROfound study), treatment of HRR-mutated mCRPC with olaparib significantly improved the median radiological progression-free survival (rPFS) compared with enzalutamide or abiraterone in patients with mutations in BRCA1, BRCA2, or ATM (7.4 months vs. 3.6 months); when patients with mutations in other genes involved in the HRR pathway (BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D, or RAD54L) were included in the analysis, rPFS was still significantly improved (5.8 months vs. 3.5 months). The confirmed objective response rate (33% vs. 2%) and median overall survival (19.1 months vs. 14.7 months) were also significantly improved in patients with BRCA1, BRCA2, or ATM mutations. Prior taxane therapy did not affect the results compared to patients who had not previously received a taxane. Olaparib is not indicated for patients with PPP2R2A mutations due to an unfavorable risk-benefit.[58662] [65472] [65930]

    for the treatment of deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC), in combination with abiraterone and prednisone or prednisolone

    Oral dosage

    Adults

    300 mg PO twice daily in combination with abiraterone (1,000 mg PO once daily) and either prednisone or prednisolone (5 mg PO twice daily) until disease progression or unacceptable toxicity. Patients should concurrently receive treatment with a gonadotropin-releasing hormone (GnRH) analog or have had a bilateral orchiectomy. Coadministration of certain drugs may need to be avoided or dosage adjustments may be necessary; review drug interactions. In a multicenter, randomized, double-blind clinical trial (PROpel), treatment with olaparib in combination with abiraterone and prednisone or prednisolone significantly improved median radiological progression-free survival (not reached vs. 8 months) and median overall survival (not reached vs. 23 months) compared with placebo plus abiraterone and prednisone/prednisolone in patients with metastatic castration-resistant prostate cancer. Prior treatment with docetaxel for localized or metastatic hormone-sensitive prostate cancer was allowed; patients with prior treatment with abiraterone were excluded.[69052] [58662]

    Therapeutic Drug Monitoring

    Dosage Adjustments for Treatment-Related Toxicity:

     

    General

    • Consider an interruption of treatment or a dose reduction of olaparib. The recommended dose of olaparib for treatment-related toxicity is 250 mg PO twice daily; the dose may be further reduced to 200 mg PO twice daily for additional toxicities.[58662]

     

    Hematologic

    • Do not start olaparib until hematologic toxicity from previous chemotherapy is grade 1 or less. For prolonged olaparib-related hematologic toxicity, hold olaparib therapy and monitor blood counts weekly until recovery to grade 1 or less. If hematologic toxicity has not recovered to grade 1 or less within 4 weeks, perform a bone marrow analysis with cytogenetics. Discontinue olaparib if a diagnosis of myelodysplastic syndrome or acute myeloid leukemia is confirmed.[58662]

    Maximum Dosage Limits

    • Adults

      300 mg PO twice daily.

    • Geriatric

      300 mg PO twice daily.

    • Adolescents

      Safety and effectiveness have not been established.

    • Children

      Safety and effectiveness have not been established.

    • Infants

      Not indicated.

    • Neonates

      Not indicated.

    Patients with Hepatic Impairment Dosing

    Baseline Hepatic Impairment:

    • Mild to moderate hepatic impairment (Child-Pugh class A and B): No dosage adjustment necessary.
    • Severe hepatic impairment (Child-Pugh class C): No data are available.[58662]

    Patients with Renal Impairment Dosing

    Baseline Renal Impairment:

    • Mild renal impairment (CrCl 51 to 80 mL/min): No dosage adjustment needed.
    • Moderate renal impairment (CrCl 31 to 50 mL/min): Reduce the dose of olaparib to 200 mg PO twice daily.
    • Severe renal impairment or end-stage renal disease (CrCl 30 mL/min or less): No data are available.[58662]
    † Off-label indication
    Revision Date: 11/16/2023, 02:39:23 PM

    References

    58662 - Lynparza (olaparib) tablets package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2023 Nov.62322 - Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. NEJM. 2017;377:523-533.63696 - Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. NEJM. 2018;379:2495-2505.64904 - Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. NEJM. 2019;381(4):317-327.65472 - de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. NEJM. 2020;382(22):2091-2102.65864 - Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017;18:1274-1284.65930 - Lynparza (olaparib) tablets package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020 Dec.66532 - Poveda A, Floquet A, Ledermann JA, et al: Final overall survival results from SOLO2/ENGOT-ov21: A phase III trial assessing maintenance olaparib in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation. ASCO20 Virtual Scientific Program. Abstract 6002. Presented at press briefing on May 12, 2020.67346 - Golan T, Hammel P, Reni M, et al. Overall survival from the phase 3 POLO trial: Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. J Clin Oncol. 2021;39(3_suppl):378.67934 - Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. NEJM. 2021;384(25):2394-2405.67997 - AstraZeneca. Dear Healthcare Provider Letter (olaparib). August 26, 2022.69052 - Clarke NW, Armstrong AJ, Thiery-Vuillemin A, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid. 2022;1(9):1-16.69881 - Ray-Coquard I, Leary A, Pignata S, et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial. Annals of Oncology. 2023;34(8):681-692.

    How Supplied

    Olaparib Oral capsule

    Lynparza 50mg Capsule (00310-0657) (AstraZeneca Pharmaceuticals LP) (off market)

    Olaparib Oral tablet

    Lynparza 100mg Tablet (00310-0668) (AstraZeneca Pharmaceuticals LP) nullLynparza 100mg Tablet package photo

    Olaparib Oral tablet

    Lynparza 150mg Tablet (00310-0679) (AstraZeneca Pharmaceuticals LP) nullLynparza 150mg Tablet package photo

    Description/Classification

    Description

    Olaparib is an oral poly (ADP-ribose) polymerase (PARP) inhibitor. PARP enzymes are involved in normal cellular homeostasis, including DNA transcription, cell cycle regulation, and DNA repair. Increased cytotoxicity and anti-tumor activity has been noted in cell lines and mouse tumor models with deficiencies in BRCA. It is approved by the FDA as monotherapy for the maintenance treatment of platinum-sensitive BRCA-mutated recurrent ovarian cancer, advanced ovarian cancer, and pancreatic cancer; it is approved in combination with bevacizumab for maintenance therapy for platinum-sensitive, homologous recombination deficiency-positive ovarian cancer. It is approved as monotherapy for the adjuvant treatment of BRCA-mutated, HER2-negative high risk early breast cancer in patients who have received neoadjuvant or adjuvant chemotherapy, for previously treated BRCA-mutated, HER2-negative metastatic breast cancer, and for homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer (mCRPC) in patients who progressed after enzalutamide or abiraterone treatment. It is also approved for BRCA-mutated mCRPC in combination with abiraterone and prednisone or prednisolone. The most common adverse reactions include anemia, nausea, fatigue, vomiting, upper respiratory infection, diarrhea, and arthralgia/myalgia.[58662]

    Classifications

    • Antineoplastic and Immunomodulating Agents
      • Antineoplastics
        • Small Molecule Antineoplastic Poly (ADP-ribose) Polymerase (PARP) Inhibitors
    Revision Date: 09/15/2023, 03:48:08 PM

    References

    58662 - Lynparza (olaparib) tablets package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2023 Nov.

    Administration Information

    General Administration Information

    For storage information, see the specific product information within the How Supplied section.

    Hazardous Drugs Classification

    • NIOSH (Draft) 2020 List: Table 2
    • Approved by FDA after NIOSH 2016 list published. The manufacturer recommends this drug be handled as a hazardous drug.
    • Observe and exercise appropriate precautions for handling, preparation, administration, and disposal of hazardous drugs.
    • Use gloves to handle. Cutting, crushing, or otherwise manipulating tablets/capsules will increase exposure.[63664]

    Emetic Risk

    • Moderate/High
    • Administer routine antiemetic prophylaxis prior to treatment.[67389] [58662]

    Route-Specific Administration

    Oral Administration

    Oral Solid Formulations

    • Information on FDA-approved tests for the detection of BRCA-mutations is available at http://www.fda.gov/companiondiagnostics.
    • Store in the original bottle to protect from moisture.
    • Swallow tablets whole; do not chew, crush, dissolve, or divide tablets.
    • Olaparib may be administered with or without food. The patient should avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange juice during treatment since these fruits and juices will raise blood levels of the drug, increasing toxicity risk.
    • If a dose is missed, the patient should take the next dose at the regularly scheduled time; instruct the patient not to take 2 doses at the same time.[58662]

    Clinical Pharmaceutics Information

    From Trissel's 2‚Ñ¢ Clinical Pharmaceutics Database
      Revision Date: 03/22/2022, 05:16:24 PM

      References

      58662 - Lynparza (olaparib) tablets package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2023 Nov.63664 - CDC National Institute for Occupational Safety and Health (NIOSH). NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2016. DHHS (NIOSH) Publication Number 2016-161, September 2016. Available on the World Wide Web at https://www.cdc.gov/niosh/docs/2016-161/pdfs/2016-161.pdf?id=10.26616/NIOSHPUB201616167389 - Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol. 2020 Aug 20;38(24):2782-2797.

      Adverse Reactions

      Mild

      • abdominal pain
      • anorexia
      • arthralgia
      • asthenia
      • back pain
      • cough
      • diarrhea
      • dizziness
      • dysgeusia
      • dyspepsia
      • fatigue
      • headache
      • infection
      • influenza
      • lethargy
      • malaise
      • myalgia
      • nausea
      • pharyngitis
      • rash
      • rhinitis
      • sinusitis
      • vertigo
      • vomiting

      Moderate

      • anemia
      • colitis
      • constipation
      • dyspnea
      • edema
      • erythema
      • hypomagnesemia
      • leukopenia
      • lymphopenia
      • neutropenia
      • oral ulceration
      • pneumonitis
      • stomatitis
      • thrombocytopenia

      Severe

      • abdominal pain
      • anemia
      • angioedema
      • anorexia
      • arthralgia
      • diarrhea
      • dizziness
      • dyspnea
      • erythema nodosum
      • fatigue
      • GI perforation
      • headache
      • infection
      • leukemia
      • leukopenia
      • nausea
      • neutropenia
      • new primary malignancy
      • pulmonary embolism
      • renal failure (unspecified)
      • stomatitis
      • stroke
      • thrombocytopenia
      • thromboembolism
      • vomiting

      New primary malignancy, specifically myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML), has been reported in 1.2% of patients treated with olaparib as monotherapy or as part of a combination regimen in clinical trials and long-term follow-up (n = 2,219); 54% of these cases had a fatal outcome. All patients who developed MDS/AML had received previous chemotherapy with platinum agents and/or other DNA damaging agents including radiation therapy. Monitor complete blood counts at baseline and monthly thereafter; do not start olaparib until hematologic toxicity from previous chemotherapy has recovered to grade 1 or less. Hold olaparib therapy for prolonged hematologic toxicity and monitor blood counts weekly until recovery. Refer patients to a hematologist for bone marrow analysis and cytogenetics if blood counts do not recover to grade 1 or less within 4 weeks. Discontinue olaparib therapy if a diagnosis of MDS or AML is confirmed.[58662]

      Infection was reported in up to 36% of patients treated with olaparib in clinical trials. Upper respiratory tract infections occurred most often, including influenza, naso-pharyngitis, bronchitis, sinusitis, rhinitis (17% to 36%; grade 3 or 4, 1% or less); nasopharyngitis (12%) and pneumonia (5%) were reported individually in separate clinical trials. A urinary tract infection was reported in 13% (grade 3 or 4, 1%) of olaparib-treated patients in one clinical trial.[58662]

      Neutropenia (9% to 27%; grade 3 or 4, 9% or less) and leukopenia (5% to 25%; grade 3 or 4, 5% or less) of patients who received olaparib as monotherapy or in combination with bevacizumab across clinical trials; neutropenic fever has occurred in patients treated with olaparib. Lymphopenia occurred in 1% to 8% of patients who received olaparib monotherapy, in 14% (grade 3 or 4, 5%) of patients who received olaparib plus abiraterone, and in 24% (grade 3 or 4, 7%) of patients who received olaparib plus bevacizumab. Decreases from baseline in leukocytes (50% to 71%; grade 3 or 4, 3% to 8%), lymphocytes (61% to 77%; grade 3 or 4, 9% to 23%) and neutrophils (23% to 51%; grade 3 or 4, 3% to 11%) were additionally reported across clinical trials in patients receiving olaparib as monotherapy or in combination with bevacizumab or abiraterone.[58662]

      Increased creatinine was reported as an adverse reaction in 2% to 11% of patients treated with olaparib monotherapy across clinical trials; however, a mild (grade 1 or 2) increase in creatinine from baseline in laboratory parameters was reported more commonly (34% to 99%). Grade 3 or 4 increases in creatinine from baseline (renal failure (unspecified)) occurred in 2% or fewer patients. In general, treatment with olaparib generally increased creatinine from baseline approximately 15% to 31% more often than placebo.[58662]

      Nausea was reported in 41% to 77% of patients treated with olaparib monotherapy across clinical trials (grade 3 or 4, 3% or less); vomiting occurred in 18% to 40% of patients (grade 3 or 4, 3% or less). The incidence of nausea (53%; grade 3 or 4, 2.4%) and vomiting (22%; grade 3 or 4, 1.7%) were similar in ovarian cancer patients receiving maintenance therapy with olaparib plus bevacizumab. Nausea was reported in 30% (grade 3 or 4, 0.3%) of patients with metastatic prostate cancer treated with olaparib plus abiraterone compared with 14% (grade 3 or 4, 0.3%) of those receiving abiraterone plus placebo; vomiting was not reported in this trial.[58662]

      Abdominal pain (45% or less; grade 3 or 4, 2% or less), diarrhea (including colitis and gastroenteritis) (18% to 37%; grade 3 or 4, 3% or less), and constipation (28% or less) occurred in patients treated with olaparib monotherapy across clinical trials; upper abdominal pain was separately reported in 4.9% to 7% of patients in 2 clinical trials. The incidence of diarrhea (18%) was similar in ovarian cancer patients receiving maintenance therapy with olaparib plus bevacizumab. Abdominal pain (13%) and diarrhea (19%; grade 3 or 4, 1%) were also reported in metastatic prostate cancer patients treated with olaparib plus abiraterone.[58662]

      Stomatitis (including aphthous ulcer, oral ulceration, oral abscess, oral herpes, and oral infection) occurred in 2.5% to 20%; grade 3 or 4, 1% or less) of patients treated with olaparib as monotherapy or in combination with bevacizumab or abiraterone across clinical trials.[58662]

      Anorexia was reported in 13% to 30% of patients treated with olaparib as monotherapy or in combination with bevacizumab or abiraterone across clinical trials (grade 3 or 4, 3% or less); dysgeusia (7% to 27%) and dyspepsia (4.3% to 17%) were also reported in olaparib-treated patients.[58662]

      One patient receiving olaparib salvage treatment for advanced ovarian cancer after at least 3 prior chemotherapy regimens died due to GI perforation in pooled data of 6 clinical trials.[58662]

      Mild (grade 1 or 2) arthralgia/myalgia was reported in 30% of patients receiving olaparib maintenance therapy for advanced ovarian cancer (n = 195) compared with 28% of those who received placebo (n = 99) in a randomized, double-blind clinical trial. Arthralgia was reported in 15% (grade 3 or 4, 1%) of patients with metastatic pancreatic cancer receiving olaparib maintenance therapy (n = 91) compared with 10% of those receiving placebo (n = 60) in one randomized clinical trial; back pain occurred in 19% of olaparib-treated patients in this trial.[58662]

      Fatigue (including asthenia, lethargy, and malaise) was reported in 37% to 67% (grade 3 or 4, 1.8% to 5%) of olaparib-treated patients in clinical trials of patients receiving olaparib maintenance therapy. Fatigue was less common in 3 clinical trials of patients receiving treatment for metastatic breast cancer or metastatic prostate cancer (37% to 41%; grade 3 or 4, 2.3% to 4%). The incidence of fatigue (53%; grade 3 or 4, 5%) was similar in ovarian cancer patients receiving maintenance therapy with olaparib plus bevacizumab.[58662]

      Hypomagnesemia was reported in 14% of patients receiving olaparib maintenance therapy for advanced ovarian cancer (n = 195) in a randomized, double-blind clinical trial.[58662]

      Rash (up to 15%) and dermatitis (up to 1%) have been reported in patients receiving olaparib as treatment or maintenance therapy in clinical trials; the term rash included erythematous rash and maculopapular rash. Rash, dermatitis, and erythema nodosum have also been reported in postmarketing experience with olaparib.[58662]

      Edema was reported in 8% of patients treated with olaparib maintenance therapy for advanced ovarian cancer in one clinical trial.[58662]

      Thromboembolism/venous thromboembolic events (VTE) including severe or fatal pulmonary embolism (PE) have been reported with olaparib therapy. Monitor patients for signs and symptoms of venous thrombosis and PE; treat VTE as medically appropriate which may include the use of long-term anticoagulation. In combined data of 2 randomized, placebo-controlled trials (n = 1,180), VTE (8% vs. 2.5%) and PE (6% vs 1.5%) occurred more often in patients with metastatic castration-resistant prostate cancer treated with olaparib plus androgen deprivation therapy (ADT) or abiraterone compared to control arms. In other randomized controlled trials, VTE occurred in 0.5% to 5% and PE in 3.5% or fewer patients who received olaparib.[58662]

      One patient receiving olaparib salvage treatment for advanced ovarian cancer after at least 3 prior chemotherapy regimens died due to stroke in pooled data of 6 clinical trials.[58662]

      Headache occurred in 6% to 26% (grade 3 or 4, 1% or less) and dizziness in 2.6% to 20% (grade 3 or 4, 0.3% or less) of olaparib-treated patients across clinical trials; the term dizziness included vertigo in 1 clinical trial.[58662]

      Pneumonitis, including some fatalities, was reported in 0.8% of patients treated with olaparib across clinical trials (n = 2,901). Pneumonitis occurred in 2% of patients with metastatic castration-resistant prostate cancer treated with olaparib plus androgen deprivation therapy. Hold olaparib therapy for new or worsening respiratory symptoms, including dyspnea, fever, cough, wheezing, or radiological abnormalities; discontinue olaparib if a diagnosis of pneumonitis is confirmed. Cough (9% to 18%) and dyspnea (4.2% to 15%; grade 3 or 4, 2% or less) have also been reported in patients treated with olaparib monotherapy. The incidence of dyspnea (8%) was similar in ovarian cancer patients receiving maintenance therapy with olaparib plus bevacizumab.[58662]

      Erythema was reported in 3% of ovarian cancer patients receiving maintenance therapy with olaparib plus bevacizumab.[58662]

      Anemia was the most common hematologic adverse reaction reported with olaparib treatment as monotherapy or in combination with bevacizumab or abiraterone, occurring in 24% to 48% (grade 3 or 4, 9% to 21%) of olaparib-treated patients across clinical trials; a decrease in hemoglobin from baseline was also reported in olaparib treatment arms (up to 98%; grade 3 or 4, 8% to 19%). A mild increase in mean corpuscular volume above normal limits (57% to 89%) was additionally reported across clinical trials. Increased mean cell volume was reported in 0.4% of patients receiving olaparib as first-line maintenance therapy for ovarian cancer.[58662]

      Thrombocytopenia occurred in 4.2% to 14% (grade 3 or 4, 4% or less) of patients receiving single-agent olaparib as treatment or maintenance therapy across clinical trials. Decreases from baseline in platelets counts were additionally reported in 23% to 56% of olaparib-treated patients (grade 3 or 4, 1% to 3%).[58662]

      Hypersensitivity reactions including angioedema have been reported in postmarketing experience in patients treated with olaparib; hypersensitivity to olaparib has been reported in 0.9% to 2% of patients.[58662]

      Revision Date: 11/20/2023, 12:02:30 PM

      References

      58662 - Lynparza (olaparib) tablets package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2023 Nov.

      Contraindications/Precautions

      Absolute contraindications are italicized.

      • bone marrow suppression
      • breast-feeding
      • chemotherapy
      • chronic lung disease (CLD)
      • contraception requirements
      • male-mediated teratogenicity
      • new primary malignancy
      • pneumonitis
      • pregnancy
      • pregnancy testing
      • pulmonary disease
      • radiation therapy
      • reproductive risk
      • thromboembolism

      New primary malignancy, specifically myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), has been reported in patients treated with olaparib monotherapy; approximately half of these cases were fatal. The median duration of olaparib therapy in patients who developed MDS/AML was 2 years. All patients who developed MDS/AML had received previous chemotherapy with platinum agents and/or other DNA damaging agents including radiation therapy. Monitor complete blood counts at baseline and monthly thereafter; do not start olaparib until hematologic toxicity from previous chemotherapy has recovered to grade 1 or less. Refer patients to a hematologist for bone marrow analysis and cytogenetics if blood counts do not recover to grade 1 or less within 4 weeks. If MDS/AML is confirmed, discontinue olaparib.[58662]

      Bone marrow suppression may be increased or prolonged if olaparib is administered in combination with other myelosuppressive chemotherapy. Do not administer olaparib until hematologic toxicity from previous treatment is grade 1 or better; monitor blood counts weekly until recovery in patients with prolonged hematologic toxicity.[58662]

      Use olaparib with caution in patients with pre-existing pulmonary disease or chronic lung disease (CLD). Pneumonitis/interstitial lung disease, with some cases including fatalities, have been reported in patients treated with olaparib. Hold olaparib therapy for new or worsening respiratory or pulmonary disease symptoms, including dyspnea, fever, cough, or radiological abnormalities; discontinue olaparib if a diagnosis of pneumonitis is confirmed.[58662]

      Thromboembolism/venous thromboembolic events (VTE) including severe or fatal pulmonary embolism (PE) have been reported with olaparib therapy. Monitor patients for signs and symptoms of venous thrombosis and PE; treat VTE as medically appropriate which may include the use of long-term anticoagulation.[58662]

      Pregnancy should be avoided by females of reproductive potential during olaparib treatment and for 6 months after the last dose. Although there are no adequately controlled studies in pregnant animals or humans, olaparib can cause fetal harm or death when administered during pregnancy based on its mechanism of action and animal studies. Women who are pregnant or who become pregnant while receiving olaparib should be apprised of the potential hazard to the fetus. Olaparib caused teratogenicity and embryo-fetal toxicity in rats at exposures below those in patients receiving the recommended human dose when administered during the period of organogenesis. When given orally for 14 days before mating through day 6 of pregnancy, olaparib resulted in increased postimplantation loss at maternal exposures of approximately 7% the AUC at the recommended human dose. At exposures approximately 0.18% the exposure of the recommended dose, pregnant rats experienced increased postimplantation loss and major malformations of the eyes (anophthalmia, microphthalmia), vertebrae/ribs (extra rib or ossification center; fused or absent neural arches, ribs, and sternebrae), skull (fused exoccipital), and diaphragm (hernia). Additional abnormalities included incomplete or absent ossification of the vertebrae/sternebrae, ribs, and limbs, as well as other findings in the vertebrae/sternebrae, pelvic girdle, lung, thymus, liver, ureter, and umbilical artery.[58662]

      Counsel patients about the reproductive risk and contraception requirements during olaparib treatment. Olaparib can be teratogenic and embryotoxic if the mother is exposed during pregnancy. Females of reproductive potential should avoid pregnancy and use effective contraception during treatment and for 6 months after the last dose of olaparib. Due to the risk of male-mediated teratogenicity, male patients with female partners of reproductive potential should use effective contraception during treatment and for at least 3 months after the last dose of olaparib. Male patients should also not donate sperm during therapy and for 3 months after the last dose. Females of reproductive potential should undergo pregnancy testing prior to the initiation of olaparib treatment. Women who become pregnant while receiving olaparib should be apprised of the potential hazard to the fetus. Olaparib does not appear to cause infertility in males or females based on animal studies.[58662]

      Due to the potential for serious adverse reactions in nursing infants from olaparib, advise women to discontinue breast-feeding during treatment and for 1 month after the final dose. It is not known whether olaparib is present in human milk, although many drugs are excreted in human milk.[58662]

      Revision Date: 06/07/2023, 09:18:06 PM

      References

      58662 - Lynparza (olaparib) tablets package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2023 Nov.

      Mechanism of Action

      Olaparib inhibits poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3. PARP enzymes are involved in normal cellular functions, such as DNA transcription and DNA repair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mouse xenograft models of human cancer, both as monotherapy or following platinum-based chemotherapy. Increased cytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor models with deficiencies in BRCA and non-BRCA proteins involved in the homologous recombination repair of DNA damage and correlated with platinum response. Olaparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complex, resulting in DNA damage and cancer cell death. In prostate cancer models, PARP1 has been shown to contribute to androgen receptor (AR) activity regulation; the combination of olaparib and AR inhibition resulted in cytotoxicity in vitro and anti-tumor activity in mouse xenograft models.[58662]

      Revision Date: 06/09/2023, 03:08:22 PM

      References

      58662 - Lynparza (olaparib) tablets package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2023 Nov.

      Pharmacokinetics

      Olaparib is administered orally and shows time-dependent pharmacokinetics. It is approximately 82% protein-bound in vitro. After a single 300 mg oral dose of olaparib, the mean volume of distribution is 158 +/- 136 L in vitro. After oral dosing of radiolabeled olaparib, 86% of the radioactivity was recovered within 7 days: 44% via urine and 42% via feces. The majority (70%) of the material was excreted as metabolites. The mean terminal half-life after a single 300 mg dose of olaparib was 14.9 +/- 8.2 hours, while the apparent plasma clearance was 7.4 +/- 3.9 L/hour.[58662]

       

      Affected cytochrome P450 (CYP450) isoenzymes and drug transporters: CYP3A4

      Olaparib is extensively metabolized by oxidation reactions, with many components undergoing subsequent glucuronide or sulfate conjugation; unchanged drug accounts for only 15% and 6% of the radioactivity in urine and feces, respectively. Coadministration with itraconazole, a strong CYP3A inhibitor, increased the AUC and Cmax of olaparib by 170% and 42%, respectively, in a drug interaction trial (n = 57). Simulations suggested that a moderate CYP3A inhibitor (fluconazole) may increase the AUC and Cmax of olaparib by 121% and 14%, respectively. Concomitant use of strong and moderate CYP3A inhibitors should be avoided; if unavoidable, a dose adjustment is recommended. Coadministration with rifampicin, a strong CYP3A inducer, decreased the AUC and Cmax of olaparib by 87% and 71%, respectively, in a drug interaction trial (n = 22). Simulations suggested that a moderate CYP3A inducer (efavirenz) may decrease the AUC and Cmax of olaparib by 60% and 31%, respectively. Concomitant use of strong and moderate CYP3A inducers should be avoided; if moderate inducers are unavoidable, there is a potential for decreased efficacy of olaparib.[58662]

       

      Olaparib is also an inducer and (weak) inhibitor of CYP3A, and an inducer of CYP2B6 in vitro. In vitro, it is also an inhibitor of UGT1A1, BCRP, OATP1B1, OCT1, OCT2, OAT3, MATE1 and MATE2K. In vitro, olaparib is a substrate of and inhibitor of P-glycoprotein (P-gp). The potential for olaparib to induce P-gp has not been evaluated.[58662]

      Route-Specific Pharmacokinetics

      Oral Route

      The mean Cmax of olaparib is 5.4 mcg/mL (CV, 32%) following a single dose and 7.6 mcg/mL (CV, 35%) at steady-state. Absorption of olaparib is rapid following oral administration, with the median time to peak plasma concentrations (Tmax) of 1.5 hours. The mean AUC of olaparib is 39.2 mcg x hour/mL (CV, 44%) following a single dose and 49.2 mcg x hour/mL (CV, 44%) at steady-state; the AUC mean accumulation ratio at steady-state is 1.8. Systemic exposure to olaparib increases approximately proportionally with doses over the dose range of 25 mg to 450 mg (0.08 to 1.5 times the recommended dose); Cmax increased slightly less than proportionally for the same dose range.[58662]

       

      Coadministration of a high-fat meal (800 to 1,000 kcal with 50% fat) delayed the Tmax by 2.5 hours but did not significantly alter the extent of olaparib absorption (mean AUC increased by approximately 8%).[58662]

      Special Populations

      Hepatic Impairment

      In a hepatic impairment trial, the mean AUC and Cmax of olaparib increased by 15% and 13%, respectively, in patients with mild hepatic impairment (n = 10; Child-Pugh class A) compared to patients with normal hepatic function (n = 13). The mean AUC of olaparib increased by 8%, and the mean Cmax decreased by 13% when administered to patients with moderate hepatic impairment (n = 8; Child-Pugh class B). Hepatic impairment did not affect olaparib protein binding. Therefore total plasma exposure is representative of free drug. There are no data in patients with severe hepatic impairment (Child-Pugh class C).[58662]

      Renal Impairment

      In a renal impairment trial, the mean AUC of olaparib increased by 24% and the Cmax increased by 15% in patients with mild renal impairment (CrCl 50 to 80 mL/min; n = 13) compared to patients with normal renal function (CrCl greater than 80 mL/min; n = 12); the mean AUC and Cmax of olaparib increased by 44% and 26%, respectively, in patients with moderate renal impairment (CrCl 31 to 50 mL/min; n = 13). There was no evidence of a relationship between the extent of plasma protein binding of olaparib and creatinine clearance. No data is available for patients with severe renal impairment or end-stage renal disease.[58662]

      Revision Date: 05/26/2020, 05:36:50 PM

      References

      58662 - Lynparza (olaparib) tablets package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2023 Nov.

      Pregnancy/Breast-feeding

      pregnancy

      Pregnancy should be avoided by females of reproductive potential during olaparib treatment and for 6 months after the last dose. Although there are no adequately controlled studies in pregnant animals or humans, olaparib can cause fetal harm or death when administered during pregnancy based on its mechanism of action and animal studies. Women who are pregnant or who become pregnant while receiving olaparib should be apprised of the potential hazard to the fetus. Olaparib caused teratogenicity and embryo-fetal toxicity in rats at exposures below those in patients receiving the recommended human dose when administered during the period of organogenesis. When given orally for 14 days before mating through day 6 of pregnancy, olaparib resulted in increased postimplantation loss at maternal exposures of approximately 7% the AUC at the recommended human dose. At exposures approximately 0.18% the exposure of the recommended dose, pregnant rats experienced increased postimplantation loss and major malformations of the eyes (anophthalmia, microphthalmia), vertebrae/ribs (extra rib or ossification center; fused or absent neural arches, ribs, and sternebrae), skull (fused exoccipital), and diaphragm (hernia). Additional abnormalities included incomplete or absent ossification of the vertebrae/sternebrae, ribs, and limbs, as well as other findings in the vertebrae/sternebrae, pelvic girdle, lung, thymus, liver, ureter, and umbilical artery.[58662]

      breast-feeding

      Due to the potential for serious adverse reactions in nursing infants from olaparib, advise women to discontinue breast-feeding during treatment and for 1 month after the final dose. It is not known whether olaparib is present in human milk, although many drugs are excreted in human milk.[58662]

      Revision Date: 06/07/2023, 09:16:34 PM

      References

      58662 - Lynparza (olaparib) tablets package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2023 Nov.

      Interactions

      Level 2 (Major)

      • Adagrasib
      • Amiodarone
      • Amobarbital
      • Amoxicillin; Clarithromycin; Omeprazole
      • Apalutamide
      • Aprepitant, Fosaprepitant
      • Aspirin, ASA; Butalbital; Caffeine
      • Atazanavir
      • Atazanavir; Cobicistat
      • Berotralstat
      • Bexarotene
      • Bosentan
      • Butalbital; Acetaminophen
      • Butalbital; Acetaminophen; Caffeine
      • Butalbital; Acetaminophen; Caffeine; Codeine
      • Butalbital; Aspirin; Caffeine; Codeine
      • Carbamazepine
      • Cenobamate
      • Ceritinib
      • Chloramphenicol
      • Ciprofloxacin
      • Clarithromycin
      • Cobicistat
      • Conivaptan
      • Crizotinib
      • Cyclosporine
      • Dabrafenib
      • Danazol
      • Darunavir
      • Darunavir; Cobicistat
      • Darunavir; Cobicistat; Emtricitabine; Tenofovir alafenamide
      • Delavirdine
      • Diltiazem
      • Dronedarone
      • Duvelisib
      • Efavirenz
      • Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate
      • Efavirenz; Lamivudine; Tenofovir Disoproxil Fumarate
      • Elagolix
      • Elagolix; Estradiol; Norethindrone acetate
      • Elvitegravir; Cobicistat; Emtricitabine; Tenofovir Alafenamide
      • Elvitegravir; Cobicistat; Emtricitabine; Tenofovir Disoproxil Fumarate
      • Encorafenib
      • Enzalutamide
      • Erythromycin
      • Eslicarbazepine
      • Etravirine
      • Fedratinib
      • Fluconazole
      • Fluvoxamine
      • Fosamprenavir
      • Fosphenytoin
      • grapefruit juice
      • Idelalisib
      • Imatinib
      • Indinavir
      • Isavuconazonium
      • Isoniazid, INH; Pyrazinamide, PZA; Rifampin
      • Isoniazid, INH; Rifampin
      • Itraconazole
      • Ketoconazole
      • Lansoprazole; Amoxicillin; Clarithromycin
      • Lefamulin
      • Lenacapavir
      • Letermovir
      • Levoketoconazole
      • Lonafarnib
      • Lopinavir; Ritonavir
      • Lorlatinib
      • Lumacaftor; Ivacaftor
      • Lumacaftor; Ivacaftor
      • Mavacamten
      • Methohexital
      • Mifepristone
      • Mitotane
      • Modafinil
      • Nafcillin
      • Nefazodone
      • Nelfinavir
      • Netupitant, Fosnetupitant; Palonosetron
      • Nilotinib
      • Nirmatrelvir; Ritonavir
      • Nirogacestat
      • Omeprazole; Amoxicillin; Rifabutin
      • Pentobarbital
      • Pexidartinib
      • Phenobarbital
      • Phenobarbital; Hyoscyamine; Atropine; Scopolamine
      • Phenytoin
      • Posaconazole
      • Primidone
      • Repotrectinib
      • Ribociclib
      • Ribociclib; Letrozole
      • Rifabutin
      • Rifampin
      • Rifapentine
      • Ritlecitinib
      • Ritonavir
      • Saquinavir
      • Secobarbital
      • Sotorasib
      • St. John's Wort, Hypericum perforatum
      • Tipranavir
      • Trandolapril; Verapamil
      • Tucatinib
      • Verapamil
      • Vonoprazan; Amoxicillin; Clarithromycin
      • Voriconazole
      • Voxelotor

      Level 3 (Moderate)

      • Cholera Vaccine
      • Dengue Tetravalent Vaccine, Live
      • SARS-CoV-2 (COVID-19) vaccines
      • SARS-CoV-2 Virus (COVID-19) Adenovirus Vector Vaccine
      • SARS-CoV-2 Virus (COVID-19) mRNA Vaccine
      • SARS-CoV-2 Virus (COVID-19) Recombinant Spike Protein Nanoparticle Vaccine
      Adagrasib: (Major) Avoid coadministration of olaparib with adagrasib due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after adagrasib is discontinued. Olaparib is a CYP3A substrate and adagrasib is a strong CYP3A inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [58662] [68325] Amiodarone: (Major) Avoid coadministration of olaparib with amiodarone due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 150 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after amiodarone is discontinued. Olaparib is a CYP3A substrate and amiodarone is a moderate CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with a moderate CYP3A inhibitor is predicted to increase the olaparib Cmax by 14% and the AUC by 121%. [28224] [28896] [58662] Amobarbital: (Major) Avoid coadministration of olaparib with amobarbital due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and amobarbital is a moderate CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with a moderate CYP3A inducer is predicted to decrease the olaparib Cmax by 31% and the AUC by 60%. [49229] [58662] Amoxicillin; Clarithromycin; Omeprazole: (Major) Avoid coadministration of olaparib with clarithromycin due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after clarithromycin is discontinued. Olaparib is a CYP3A substrate and clarithromycin is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [28238] [34329] [58662] Apalutamide: (Major) Avoid coadministration of olaparib with apalutamide due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and apalutamide is a strong CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with another strong CYP3A inducer decreased the olaparib Cmax by 71% and the AUC by 87%. [58662] [62874] Aprepitant, Fosaprepitant: (Major) Avoid coadministration of olaparib for several days after a multi-day regimen of oral aprepitant due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 150 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after aprepitant is discontinued. Olaparib is a CYP3A substrate. Aprepitant is a moderate CYP3A4 inhibitor when administered as a 3-day oral regimen. Coadministration with a moderate CYP3A inhibitor is predicted to increase the olaparib Cmax by 14% and the AUC by 121%. When administered as a single oral or single intravenous dose (fosaprepitant), the inhibitory effect of aprepitant on CYP3A4 is weak and did not result in a clinically significant increase in the AUC of a sensitive substrate. [30676] [40027] [58662] Aspirin, ASA; Butalbital; Caffeine: (Major) Avoid coadministration of olaparib with butalbital due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and butalbital is a moderate CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with a moderate CYP3A inducer is predicted to decrease the olaparib Cmax by 31% and the AUC by 60%. [28001] [58662] Atazanavir: (Major) Avoid coadministration of olaparib with atazanavir due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after atazanavir is discontinued. Olaparib is a CYP3A substrate and atazanavir is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [28142] [58662] Atazanavir; Cobicistat: (Major) Avoid coadministration of olaparib with atazanavir due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after atazanavir is discontinued. Olaparib is a CYP3A substrate and atazanavir is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [28142] [58662] (Major) Avoid coadministration of olaparib with cobicistat due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after cobicistat is discontinued. Olaparib is a CYP3A substrate and cobicistat is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [58000] [58662] Berotralstat: (Major) Avoid coadministration of olaparib with berotralstat due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 150 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after berotralstat is discontinued. Olaparib is a CYP3A4 substrate and berotralstat is a moderate CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with a moderate CYP3A inhibitor is predicted to increase the olaparib Cmax by 14% and the AUC by 121%. [58662] [66159] Bexarotene: (Major) Avoid coadministration of olaparib with bexarotene due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and bexarotene is a moderate CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with a moderate CYP3A inducer is predicted to decrease the olaparib Cmax by 31% and the AUC by 60%. [58662] [59747] Bosentan: (Major) Avoid coadministration of olaparib with bosentan due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and bosentan is a moderate CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with a moderate CYP3A inducer is predicted to decrease the olaparib Cmax by 31% and the AUC by 60%. [28496] [58662] Butalbital; Acetaminophen: (Major) Avoid coadministration of olaparib with butalbital due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and butalbital is a moderate CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with a moderate CYP3A inducer is predicted to decrease the olaparib Cmax by 31% and the AUC by 60%. [28001] [58662] Butalbital; Acetaminophen; Caffeine: (Major) Avoid coadministration of olaparib with butalbital due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and butalbital is a moderate CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with a moderate CYP3A inducer is predicted to decrease the olaparib Cmax by 31% and the AUC by 60%. [28001] [58662] Butalbital; Acetaminophen; Caffeine; Codeine: (Major) Avoid coadministration of olaparib with butalbital due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and butalbital is a moderate CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with a moderate CYP3A inducer is predicted to decrease the olaparib Cmax by 31% and the AUC by 60%. [28001] [58662] Butalbital; Aspirin; Caffeine; Codeine: (Major) Avoid coadministration of olaparib with butalbital due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and butalbital is a moderate CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with a moderate CYP3A inducer is predicted to decrease the olaparib Cmax by 31% and the AUC by 60%. [28001] [58662] Carbamazepine: (Major) Avoid coadministration of olaparib with carbamazepine due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and carbamazepine is a strong CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with another strong CYP3A inducer decreased the olaparib Cmax by 71% and the AUC by 87%. [28024] [41237] [57036] [57048] [58662] Cenobamate: (Major) Avoid coadministration of olaparib with cenobamate due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and cenobamate is a moderate CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with a moderate CYP3A inducer is predicted to decrease the olaparib Cmax by 31% and the AUC by 60%. [58662] [64768] Ceritinib: (Major) Avoid coadministration of olaparib with ceritinib due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after ceritinib is discontinued. Olaparib is a CYP3A substrate and ceritinib is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [57094] [58662] Chloramphenicol: (Major) Avoid coadministration of olaparib with chloramphenicol due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after chloramphenicol is discontinued. Olaparib is a CYP3A substrate and chloramphenicol is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [29624] [58662] Cholera Vaccine: (Moderate) Patients receiving immunosuppressant medications may have a diminished response to the live cholera vaccine. When feasible, administer indicated vaccines prior to initiating immunosuppressant medications. Counsel patients receiving immunosuppressant medications about the possibility of a diminished vaccine response and to continue to follow precautions to avoid exposure to cholera bacteria after receiving the vaccine. [60871] Ciprofloxacin: (Major) Avoid coadministration of olaparib with ciprofloxacin due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 150 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after ciprofloxacin is discontinued. Olaparib is a CYP3A substrate and ciprofloxacin is a moderate CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with a moderate CYP3A inhibitor is predicted to increase the olaparib Cmax by 14% and the AUC by 121%. [30117] [34768] [34769] [34772] [34773] [56579] [58662] Clarithromycin: (Major) Avoid coadministration of olaparib with clarithromycin due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after clarithromycin is discontinued. Olaparib is a CYP3A substrate and clarithromycin is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [28238] [34329] [58662] Cobicistat: (Major) Avoid coadministration of olaparib with cobicistat due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after cobicistat is discontinued. Olaparib is a CYP3A substrate and cobicistat is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [58000] [58662] Conivaptan: (Major) Avoid coadministration of olaparib with conivaptan due to the risk of increased olaparib-related adverse reactions. If concomitant use is necessary, reduce the dose of olaparib to 150 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after conivaptan is discontinued. Olaparib is a CYP3A substrate and conivaptan is a moderate CYP3A inhibitor; concomitant use may increase olaparib exposure. Coadministration with a moderate CYP3A inhibitor is predicted to increase the olaparib peak by 14% and the overall exposure by 121%. [31764] [56579] [58662] Crizotinib: (Major) Avoid coadministration of olaparib with crizotinib due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 150 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after crizotinib is discontinued. Olaparib is a CYP3A substrate and crizotinib is a moderate CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with a moderate CYP3A inhibitor is predicted to increase the olaparib Cmax by 14% and the AUC by 121%. [45458] [58662] Cyclosporine: (Major) Avoid coadministration of olaparib with cyclosporine due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 150 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after cyclosporine is discontinued. Olaparib is a CYP3A substrate and cyclosporine is a moderate CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with a moderate CYP3A inhibitor is predicted to increase the olaparib Cmax by 14% and the AUC by 121%. [28404] [34375] [58662] Dabrafenib: (Major) Avoid coadministration of olaparib with dabrafenib due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and dabrafenib is a moderate CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with a moderate CYP3A inducer is predicted to decrease the olaparib Cmax by 31% and the AUC by 60%. [54802] [58662] Danazol: (Major) Avoid coadministration of olaparib with danazol due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 150 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after danazol is discontinued. Olaparib is a CYP3A substrate and danazol is a moderate CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with a moderate CYP3A inhibitor is predicted to increase the olaparib Cmax by 14% and the AUC by 121%. [34717] [58662] Darunavir: (Major) Avoid coadministration of olaparib with darunavir due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after darunavir is discontinued. Olaparib is a CYP3A substrate and darunavir is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [32432] [58662] [59759] Darunavir; Cobicistat: (Major) Avoid coadministration of olaparib with cobicistat due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after cobicistat is discontinued. Olaparib is a CYP3A substrate and cobicistat is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [58000] [58662] (Major) Avoid coadministration of olaparib with darunavir due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after darunavir is discontinued. Olaparib is a CYP3A substrate and darunavir is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [32432] [58662] [59759] Darunavir; Cobicistat; Emtricitabine; Tenofovir alafenamide: (Major) Avoid coadministration of olaparib with cobicistat due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after cobicistat is discontinued. Olaparib is a CYP3A substrate and cobicistat is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [58000] [58662] (Major) Avoid coadministration of olaparib with darunavir due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after darunavir is discontinued. Olaparib is a CYP3A substrate and darunavir is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [32432] [58662] [59759] Delavirdine: (Major) Avoid coadministration of olaparib with delavirdine due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after delavirdine is discontinued. Olaparib is a CYP3A substrate and delavirdine is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [28476] [58662] Dengue Tetravalent Vaccine, Live: (Moderate) Patients receiving immunosuppressant medications may have a diminished response to the dengue virus vaccine. When feasible, administer indicated vaccines at least 2 weeks prior to initiating immunosuppressant medications. If vaccine administration is necessary, consider revaccination following restoration of immune competence. Counsel patients receiving immunosuppressant medications about the possibility of a diminished vaccine response and to continue to follow precautions to avoid exposure after receiving the vaccine. [60092] [64100] [65107] Diltiazem: (Major) Avoid coadministration of olaparib with diltiazem due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 150 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after diltiazem is discontinued. Olaparib is a CYP3A substrate and diltiazem is a moderate CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with a moderate CYP3A inhibitor is predicted to increase the olaparib Cmax by 14% and the AUC by 121%. [34494] [55768] [58662] Dronedarone: (Major) Avoid coadministration of olaparib with dronedarone due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 150 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after dronedarone is discontinued. Olaparib is a CYP3A substrate and dronedarone is a moderate CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with a moderate CYP3A inhibitor is predicted to increase the olaparib Cmax by 14% and the AUC by 121%. [36101] [58662] Duvelisib: (Major) Avoid coadministration of olaparib with duvelisib due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 150 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after duvelisib is discontinued. Olaparib is a CYP3A substrate and duvelisib is a moderate CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with a moderate CYP3A inhibitor is predicted to increase the olaparib Cmax by 14% and the AUC by 121%. [58662] [63571] Efavirenz: (Major) Avoid coadministration of olaparib with efavirenz due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and efavirenz is a moderate CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with efavirenz is predicted to decrease the olaparib Cmax by 31% and the AUC by 60%. [28442] [58662] Efavirenz; Emtricitabine; Tenofovir Disoproxil Fumarate: (Major) Avoid coadministration of olaparib with efavirenz due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and efavirenz is a moderate CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with efavirenz is predicted to decrease the olaparib Cmax by 31% and the AUC by 60%. [28442] [58662] Efavirenz; Lamivudine; Tenofovir Disoproxil Fumarate: (Major) Avoid coadministration of olaparib with efavirenz due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and efavirenz is a moderate CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with efavirenz is predicted to decrease the olaparib Cmax by 31% and the AUC by 60%. [28442] [58662] Elagolix: (Major) Avoid coadministration of olaparib with elagolix due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and elagolix is a weak to moderate CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with a moderate CYP3A inducer is predicted to decrease the olaparib Cmax by 31% and the AUC by 60%. [58662] [63387] Elagolix; Estradiol; Norethindrone acetate: (Major) Avoid coadministration of olaparib with elagolix due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and elagolix is a weak to moderate CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with a moderate CYP3A inducer is predicted to decrease the olaparib Cmax by 31% and the AUC by 60%. [58662] [63387] Elvitegravir; Cobicistat; Emtricitabine; Tenofovir Alafenamide: (Major) Avoid coadministration of olaparib with cobicistat due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after cobicistat is discontinued. Olaparib is a CYP3A substrate and cobicistat is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [58000] [58662] Elvitegravir; Cobicistat; Emtricitabine; Tenofovir Disoproxil Fumarate: (Major) Avoid coadministration of olaparib with cobicistat due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after cobicistat is discontinued. Olaparib is a CYP3A substrate and cobicistat is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [58000] [58662] Encorafenib: (Major) Avoid coadministration of olaparib with encorafenib due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and encorafenib is a strong CYP3A inducer; concomitant use may decrease olaparib exposure. Coadministration with another strong CYP3A inducer decreased the olaparib Cmax by 71% and the AUC by 87%. [58662] [63317] Enzalutamide: (Major) Avoid coadministration of olaparib with enzalutamide due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and enzalutamide is a strong CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with another strong CYP3A inducer decreased the olaparib Cmax by 71% and the AUC by 87%. [51727] [58662] Erythromycin: (Major) Avoid coadministration of olaparib with erythromycin due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 150 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after erythromycin is discontinued. Olaparib is a CYP3A substrate and erythromycin is a moderate CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with a moderate CYP3A inhibitor is predicted to increase the olaparib Cmax by 14% and the AUC by 121%. [28251] [58662] Eslicarbazepine: (Major) Avoid coadministration of olaparib with eslicarbazepine due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and eslicarbazepine is a moderate CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with a moderate CYP3A inducer is predicted to decrease the olaparib Cmax by 31% and the AUC by 60%. [56436] [58662] Etravirine: (Major) Avoid coadministration of olaparib with etravirine due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and etravirine is a moderate CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with a moderate CYP3A inducer is predicted to decrease the olaparib Cmax by 31% and the AUC by 60%. [33718] [58662] Fedratinib: (Major) Avoid coadministration of olaparib with fedratinib due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 150 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after fedratinib is discontinued. Olaparib is a CYP3A substrate and fedratinib is a moderate CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with a moderate CYP3A inhibitor is predicted to increase the olaparib Cmax by 14% and the AUC by 121%. [58662] [64568] Fluconazole: (Major) Avoid coadministration of olaparib with fluconazole due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 150 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after fluconazole is discontinued. Olaparib is a CYP3A substrate and fluconazole is a moderate CYP3A4 inhibitor. Coadministration with fluconazole is predicted to increase the olaparib Cmax by 14% and the AUC by 121%. [29036] [34447] [58662] Fluvoxamine: (Major) Avoid coadministration of olaparib with fluvoxamine due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 150 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after fluvoxamine is discontinued. Olaparib is a CYP3A substrate and fluvoxamine is a moderate CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with a moderate CYP3A inhibitor is predicted to increase the olaparib Cmax by 14% and the AUC by 121%. [47184] [54631] [54632] [58662] Fosamprenavir: (Major) Avoid coadministration of olaparib with fosamprenavir due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 150 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after fosamprenavir is discontinued. Olaparib is a CYP3A substrate and fosamprenavir is a moderate CYP3A inhibitor; concomitant use may increase olaparib exposure. Coadministration with a moderate CYP3A inhibitor is predicted to increase the olaparib Cmax by 14% and the AUC by 121%. [29012] [58662] Fosphenytoin: (Major) Avoid coadministration of olaparib with fosphenytoin due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and fosphenytoin is a strong CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with another strong CYP3A inducer decreased the olaparib Cmax by 71% and the AUC by 87%. [22005] [56579] [57046] [57080] [57105] [58662] Grapefruit juice: (Major) Due to the potential for increased olaparib exposure and side effects, patients should be advised to avoid intake of grapefruit, grapefruit juice, Seville oranges, and Seville orange juice during olaparib therapy. Olaparib is a CYP3A substrate and both grapefruit and Seville oranges are strong CYP3A4 inhibitors. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [29087] [58104] [58662] Idelalisib: (Major) Avoid coadministration of olaparib with idelalisib due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after idelalisib is discontinued. Olaparib is a CYP3A substrate and idelalisib is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [57675] [58662] Imatinib: (Major) Avoid coadministration of olaparib with imatinib due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 150 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after imatinib is discontinued. Olaparib is a CYP3A substrate and imatinib is a moderate CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with a moderate CYP3A inhibitor is predicted to increase the olaparib Cmax by 14% and the AUC by 121%. [34514] [58662] [58770] Indinavir: (Major) Avoid coadministration of olaparib with indinavir due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after indinavir is discontinued. Olaparib is a CYP3A substrate and indinavir is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [28731] [34557] [58662] Isavuconazonium: (Major) Avoid coadministration of olaparib with isavuconazonium due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 150 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after isavuconazonium is discontinued. Olaparib is a CYP3A substrate and isavuconazonium is a moderate CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with a moderate CYP3A inhibitor is predicted to increase the olaparib Cmax by 14% and the AUC by 121%. [58662] [59042] Isoniazid, INH; Pyrazinamide, PZA; Rifampin: (Major) Avoid coadministration of olaparib with rifampin due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and rifampin is a strong CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with rifampin decreased the olaparib Cmax by 71% and the AUC by 87%. [58662] Isoniazid, INH; Rifampin: (Major) Avoid coadministration of olaparib with rifampin due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and rifampin is a strong CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with rifampin decreased the olaparib Cmax by 71% and the AUC by 87%. [58662] Itraconazole: (Major) Avoid coadministration of olaparib with itraconazole due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after itraconazole is discontinued. Olaparib is a CYP3A substrate and itraconazole is a strong CYP3A4 inhibitor. Coadministration with itraconazole increased the olaparib Cmax by 42% and the AUC by 170%. [27983] [40233] [58662] Ketoconazole: (Major) Avoid coadministration of olaparib with ketoconazole due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after ketoconazole is discontinued. Olaparib is a CYP3A substrate and ketoconazole is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [27982] [58662] Lansoprazole; Amoxicillin; Clarithromycin: (Major) Avoid coadministration of olaparib with clarithromycin due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after clarithromycin is discontinued. Olaparib is a CYP3A substrate and clarithromycin is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [28238] [34329] [58662] Lefamulin: (Major) Avoid coadministration of olaparib with oral lefamulin due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 150 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after lefamulin is discontinued. Olaparib is a CYP3A substrate and oral lefamulin is a moderate CYP3A4 inhibitor; an interaction is not expected with intravenous lefamulin. Concomitant use may increase olaparib exposure. Coadministration with another moderate CYP3A inhibitor is predicted to increase the olaparib Cmax by 14% and the AUC by 121%. [58662] [64576] Lenacapavir: (Major) Avoid coadministration of olaparib with lenacapavir due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 150 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after lenacapavir is discontinued. Olaparib is a CYP3A substrate and lenacapavir is a moderate CYP3A inhibitor; concomitant use may increase olaparib exposure. Coadministration with a moderate CYP3A inhibitor is predicted to increase the olaparib AUC by 121%. [58662] [68383] Letermovir: (Major) Avoid coadministration of olaparib with letermovir due to the risk of increased olaparib-related adverse reactions. In patients who are also receiving treatment with cyclosporine, the magnitude of this interaction may be amplified. If concomitant use is unavoidable, reduce the dose of olaparib to 150 mg twice daily if patients are taking letermovir without cyclosporine. If olaparib must be given with both letermovir and cyclosporine, reduce the dose of olaparib to 100 mg twice daily. The original dose of olaparib may be resumed 3 to 5 elimination half-lives after letermovir is discontinued. Olaparib is a CYP3A substrate. Letermovir is a moderate CYP3A4 inhibitor; however, the combined effect of letermovir and cyclosporine on CYP3A4 substrates may be similar to a strong CYP3A4 inhibitor. Coadministration with a moderate CYP3A inhibitor is predicted to increase the olaparib Cmax by 14% and the AUC by 121%. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [58662] [62611] Levoketoconazole: (Major) Avoid coadministration of olaparib with ketoconazole due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after ketoconazole is discontinued. Olaparib is a CYP3A substrate and ketoconazole is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [27982] [58662] Lonafarnib: (Major) Avoid coadministration of olaparib with lonafarnib due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after lonafarnib is discontinued. Olaparib is a CYP3A4 substrate and lonafarnib is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A4 inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [58662] [66129] Lopinavir; Ritonavir: (Major) Avoid coadministration of olaparib with ritonavir due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after ritonavir is discontinued. Olaparib is a CYP3A substrate and ritonavir is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [28380] [34557] [47165] [58662] Lorlatinib: (Major) Avoid coadministration of olaparib with lorlatinib due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and lorlatinib is a moderate CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with a moderate CYP3A inducer is predicted to decrease the olaparib Cmax by 31% and the AUC by 60%. [58662] [63732] Lumacaftor; Ivacaftor: (Major) Avoid coadministration of olaparib with lumacaftor; ivacaftor due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and lumacaftor is a strong CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with another strong CYP3A inducer decreased the olaparib Cmax by 71% and the AUC by 87%. [58662] [59891] Lumacaftor; Ivacaftor: (Major) Avoid coadministration of olaparib with lumacaftor; ivacaftor due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and lumacaftor is a strong CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with another strong CYP3A inducer decreased the olaparib Cmax by 71% and the AUC by 87%. [58662] [59891] Mavacamten: (Major) Avoid coadministration of olaparib with mavacamten due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and mavacamten is a moderate CYP3A inducer; concomitant use may decrease olaparib exposure. Coadministration with a moderate CYP3A inducer is predicted to decrease the olaparib Cmax by 31% and the AUC by 60%. [58662] [67543] Methohexital: (Major) Avoid coadministration of olaparib with methohexital due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and methohexital is a moderate CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with a moderate CYP3A inducer is predicted to decrease the olaparib Cmax by 31% and the AUC by 60%. [41911] [58662] Mifepristone: (Major) Avoid coadministration of olaparib with mifepristone due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after mifepristone is discontinued. Olaparib is a CYP3A substrate and mifepristone is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. The clinical significance of this interaction with the short-term use of mifepristone for termination of pregnancy is unknown. [28003] [48697] [58662] Mitotane: (Major) Avoid coadministration of olaparib with mitotane due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and mitotane is a strong CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with another strong CYP3A inducer decreased the olaparib Cmax by 71% and the AUC by 87%. [41934] [58662] Modafinil: (Major) Avoid coadministration of olaparib with modafinil due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and modafinil is a moderate CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with a moderate CYP3A inducer is predicted to decrease the olaparib Cmax by 31% and the AUC by 60%. [41243] [58662] Nafcillin: (Major) Avoid coadministration of olaparib with nafcillin due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and nafcillin is a moderate CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with a moderate CYP3A inducer is predicted to decrease the olaparib Cmax by 31% and the AUC by 60%. [34455] [34456] [58662] Nefazodone: (Major) Avoid coadministration of olaparib with nefazodone due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after nefazodone is discontinued. Olaparib is a CYP3A substrate and nefazodone is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [28683] [54634] [58662] Nelfinavir: (Major) Avoid coadministration of olaparib with nelfinavir due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after nelfinavir is discontinued. Olaparib is a CYP3A substrate and nelfinavir is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [28839] [34558] [34559] [58662] Netupitant, Fosnetupitant; Palonosetron: (Major) Avoid coadministration of olaparib with netupitant due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 150 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after netupitant is discontinued. Olaparib is a CYP3A substrate and netupitant is a moderate CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with a moderate CYP3A inhibitor is predicted to increase the olaparib Cmax by 14% and the AUC by 121%. [58171] [58662] Nilotinib: (Major) Avoid coadministration of olaparib with nilotinib due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 150 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after nilotinib is discontinued. Olaparib is a CYP3A substrate and nilotinib is a moderate CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with a moderate CYP3A inhibitor is predicted to increase the olaparib Cmax by 14% and the AUC by 121%. [33557] [58662] Nirmatrelvir; Ritonavir: (Major) Avoid coadministration of olaparib with ritonavir due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after ritonavir is discontinued. Olaparib is a CYP3A substrate and ritonavir is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [28380] [34557] [47165] [58662] Nirogacestat: (Major) Avoid coadministration of olaparib with nirogacestat due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 150 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after nirogacestat is discontinued. Olaparib is a CYP3A substrate and nirogacestat is a moderate CYP3A inhibitor; concomitant use may increase olaparib exposure. Coadministration with a moderate CYP3A inhibitor is predicted to increase the olaparib AUC by 121%. [58662] [69917] Omeprazole; Amoxicillin; Rifabutin: (Major) Avoid coadministration of olaparib with rifabutin due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and rifabutin is a moderate CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with a moderate CYP3A inducer is predicted to decrease the olaparib Cmax by 31% and the AUC by 60%. [29210] [29812] [34549] [34550] [58662] Pentobarbital: (Major) Avoid coadministration of olaparib with pentobarbital due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and pentobarbital is a moderate CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with a moderate CYP3A inducer is predicted to decrease the olaparib Cmax by 31% and the AUC by 60%. [58662] Pexidartinib: (Major) Avoid coadministration of olaparib with pexidartinib due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A4 substrate and pexidartinib is a moderate CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with a moderate CYP3A4 inducer is predicted to decrease the olaparib Cmax by 31% and the AUC by 60%. [58662] [64535] Phenobarbital: (Major) Avoid coadministration of olaparib with phenobarbital due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and phenobarbital is a strong CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with another strong CYP3A inducer decreased the olaparib Cmax by 71% and the AUC by 87%. [22005] [55436] [57046] [57048] [57080] [58662] Phenobarbital; Hyoscyamine; Atropine; Scopolamine: (Major) Avoid coadministration of olaparib with phenobarbital due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and phenobarbital is a strong CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with another strong CYP3A inducer decreased the olaparib Cmax by 71% and the AUC by 87%. [22005] [55436] [57046] [57048] [57080] [58662] Phenytoin: (Major) Avoid coadministration of olaparib with phenytoin due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and phenytoin is a strong CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with another strong CYP3A inducer decreased the olaparib Cmax by 71% and the AUC by 87%. [22005] [55436] [56579] [57046] [57080] [57105] [58662] Posaconazole: (Major) Avoid coadministration of olaparib with posaconazole due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after posaconazole is discontinued. Olaparib is a CYP3A substrate and posaconazole is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [32723] [34464] [34465] [58662] Primidone: (Major) Avoid coadministration of olaparib with primidone due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and primidone is a strong CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with another strong CYP3A inducer decreased the olaparib Cmax by 71% and the AUC by 87%. [22005] [57046] [57048] [57080] [58662] Repotrectinib: (Major) Avoid coadministration of olaparib with repotrectinib due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and repotrectinib is a moderate CYP3A inducer; concomitant use may decrease olaparib exposure. Coadministration with a moderate CYP3A inducer is predicted to decrease the olaparib Cmax by 31% and the AUC by 60%. [58662] [69884] Ribociclib: (Major) Avoid coadministration of olaparib with ribociclib due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after ribociclib is discontinued. Olaparib is a CYP3A substrate and ribociclib is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [58662] [61816] Ribociclib; Letrozole: (Major) Avoid coadministration of olaparib with ribociclib due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after ribociclib is discontinued. Olaparib is a CYP3A substrate and ribociclib is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [58662] [61816] Rifabutin: (Major) Avoid coadministration of olaparib with rifabutin due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and rifabutin is a moderate CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with a moderate CYP3A inducer is predicted to decrease the olaparib Cmax by 31% and the AUC by 60%. [29210] [29812] [34549] [34550] [58662] Rifampin: (Major) Avoid coadministration of olaparib with rifampin due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and rifampin is a strong CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with rifampin decreased the olaparib Cmax by 71% and the AUC by 87%. [58662] Rifapentine: (Major) Avoid coadministration of olaparib with rifapentine due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A4 substrate and rifapentine is a strong CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with another strong CYP3A4 inducer decreased the olaparib Cmax by 71% and the AUC by 87%. [58662] [65685] Ritlecitinib: (Major) Avoid coadministration of olaparib with ritlecitinib due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 150 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after ritlecitinib is discontinued. Olaparib is a CYP3A substrate and ritlecitinib is a moderate CYP3A inhibitor; concomitant use may increase olaparib exposure. Coadministration with a moderate CYP3A inhibitor is predicted to increase the olaparib AUC by 121%. [58662] [69127] Ritonavir: (Major) Avoid coadministration of olaparib with ritonavir due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after ritonavir is discontinued. Olaparib is a CYP3A substrate and ritonavir is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [28380] [34557] [47165] [58662] Saquinavir: (Major) Avoid coadministration of olaparib with saquinavir due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after saquinavir is discontinued. Olaparib is a CYP3A substrate and saquinavir is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [28995] [34557] [34558] [39863] [39864] [58662] SARS-CoV-2 (COVID-19) vaccines: (Moderate) Patients receiving immunosuppressant medications may have a diminished response to the SARS-CoV-2 virus vaccine. When feasible, administer indicated vaccines prior to initiating immunosuppressant medications. Counsel patients receiving immunosuppressant medications about the possibility of a diminished vaccine response and to continue to follow precautions to avoid exposure to SARS-CoV-2 virus after receiving the vaccine. [65107] [66080] SARS-CoV-2 Virus (COVID-19) Adenovirus Vector Vaccine: (Moderate) Patients receiving immunosuppressant medications may have a diminished response to the SARS-CoV-2 virus vaccine. When feasible, administer indicated vaccines prior to initiating immunosuppressant medications. Counsel patients receiving immunosuppressant medications about the possibility of a diminished vaccine response and to continue to follow precautions to avoid exposure to SARS-CoV-2 virus after receiving the vaccine. [65107] [66080] SARS-CoV-2 Virus (COVID-19) mRNA Vaccine: (Moderate) Patients receiving immunosuppressant medications may have a diminished response to the SARS-CoV-2 virus vaccine. When feasible, administer indicated vaccines prior to initiating immunosuppressant medications. Counsel patients receiving immunosuppressant medications about the possibility of a diminished vaccine response and to continue to follow precautions to avoid exposure to SARS-CoV-2 virus after receiving the vaccine. [65107] [66080] SARS-CoV-2 Virus (COVID-19) Recombinant Spike Protein Nanoparticle Vaccine: (Moderate) Patients receiving immunosuppressant medications may have a diminished response to the SARS-CoV-2 virus vaccine. When feasible, administer indicated vaccines prior to initiating immunosuppressant medications. Counsel patients receiving immunosuppressant medications about the possibility of a diminished vaccine response and to continue to follow precautions to avoid exposure to SARS-CoV-2 virus after receiving the vaccine. [65107] [66080] Secobarbital: (Major) Avoid coadministration of olaparib with secobarbital due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and secobarbital is a moderate CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with a moderate CYP3A inducer is predicted to decrease the olaparib Cmax by 31% and the AUC by 60%. [49352] [58662] Sotorasib: (Major) Avoid coadministration of olaparib with sotorasib due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A4 substrate and sotorasib is a moderate CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with a moderate CYP3A4 inducer is predicted to decrease the olaparib Cmax by 31% and the AUC by 60%. [58662] [66700] St. John's Wort, Hypericum perforatum: (Major) Avoid coadministration of olaparib with St. Johns Wort due to the risk of decreasing the efficacy of olaparib. Olaparib is a CYP3A substrate and St. Johns Wort is a strong CYP3A4 inducer; concomitant use may decrease olaparib exposure. Coadministration with another strong CYP3A inducer decreased the olaparib Cmax by 71% and the AUC by 87%. [57202] [57852] [58662] Tipranavir: (Major) Avoid coadministration of olaparib with tipranavir due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after tipranavir is discontinued. Olaparib is a CYP3A substrate and tipranavir is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [31320] [58662] Trandolapril; Verapamil: (Major) Avoid coadministration of olaparib with verapamil due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 150 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after verapamil is discontinued. Olaparib is a CYP3A substrate and verapamil is a moderate CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with a moderate CYP3A inhibitor is predicted to increase the olaparib Cmax by 14% and the AUC by 121%. [29702] [34695] [40025] [58662] Tucatinib: (Major) Avoid coadministration of olaparib with tucatinib due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after tucatinib is discontinued. Olaparib is a CYP3A4 substrate and tucatinib is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A4 inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [58662] [65295] Verapamil: (Major) Avoid coadministration of olaparib with verapamil due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 150 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after verapamil is discontinued. Olaparib is a CYP3A substrate and verapamil is a moderate CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with a moderate CYP3A inhibitor is predicted to increase the olaparib Cmax by 14% and the AUC by 121%. [29702] [34695] [40025] [58662] Vonoprazan; Amoxicillin; Clarithromycin: (Major) Avoid coadministration of olaparib with clarithromycin due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after clarithromycin is discontinued. Olaparib is a CYP3A substrate and clarithromycin is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [28238] [34329] [58662] Voriconazole: (Major) Avoid coadministration of olaparib with voriconazole due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 100 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after voriconazole is discontinued. Olaparib is a CYP3A substrate and voriconazole is a strong CYP3A4 inhibitor; concomitant use may increase olaparib exposure. Coadministration with another strong CYP3A inhibitor increased the olaparib Cmax by 42% and the AUC by 170%. [28158] [54713] [58662] Voxelotor: (Major) Avoid coadministration of olaparib with voxelotor due to the risk of increased olaparib-related adverse reactions. If concomitant use is unavoidable, reduce the dose of olaparib to 150 mg twice daily; the original dose may be resumed 3 to 5 elimination half-lives after voxelotor is discontinued. Olaparib is a CYP3A substrate and voxelotor is a moderate CYP3A inhibitor; concomitant use may increase olaparib exposure. Coadministration with a moderate CYP3A inhibitor is predicted to increase the olaparib Cmax by 14% and the AUC by 121%. [58662] [64778]
      Revision Date: 01/11/2024, 04:54:00 PM

      References

      22005 - Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006;61(3):246-255.27982 - Ketoconazole tablets package insert. Morgantown, WV: Mylan Pharmaceuticals, Inc.; 2017 Sept.27983 - Sporanox (itraconazole) capsules package insert. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2024 Feb.28001 - Hansten PD, Horn JR. Cytochrome P450 Enzymes and Drug Interactions, Table of Cytochrome P450 Substrates, Inhibitors, Inducers and P-glycoprotein, with Footnotes. In: The Top 100 Drug Interactions - A guide to Patient Management. 2008 Edition. Freeland, WA: H&H Publications; 2008:142-157.28003 - Mifeprex (Mifepristone, RU-486) package insert. New York, NY: Danco Laboratories, LLC.; 2023 Mar.28024 - Carbatrol (carbamazepine extended-release capsules) package insert. Lexington, MA: Takeda Pharmaceuticals America, Inc.; 2023 Apr.28142 - Reyataz (atazanavir) package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2023 Nov.28158 - VFEND (voriconazole) tablets, suspension, and injection package insert. New York, NY: Pfizer Inc; 2022 Oct.28224 - Pacerone (amiodarone) tablets package insert. Maple Grove, MN: Upsher-Smith Laboratories, LLC.; 2018 Nov.28238 - Biaxin (clarithromycin) package insert. North Chicago, IL: AbbVie, Inc.; 2019 Sep.28251 - Ery-tab (erythromycin delayed-release tablets) package insert. Atlanta, GA: Arbor Pharmaceuticals, Inc.; 2018 Oct.28380 - Phillips E, Rachlis A, Ito S. Digoxin toxicity and ritonavir: a drug interaction mediated through p-glycoprotein? AIDS 2003;17:1577-8.28404 - Neoral (cyclosporine) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2023 Sept.28442 - Sustiva (efavirenz) package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2023 Nov.28476 - Rescriptor (delavirdine) package insert. Research Triangle Park, NC: ViiV Healthcare; 2019 Aug.28496 - Tracleer (bosentan) package insert. Titusville, NJ: Actelion Pharmaceuticals US, Inc.; 2024 Feb.28683 - Nefazodone tablet package insert. North Wales, PA: Teva Pharmaceuticals USA, Inc.; 2015 Sept.28731 - Crixivan (indinavir) package insert. Whitehouse Station, NJ: Merck & Co., Inc.; 2016 Sept.28839 - Viracept (nelfinavir mesylate) package insert. Research Triangle Park, NC: ViiV Healthcare Company; 2021 Mar.28896 - Yamreudeewong W, DeBisschop M, Martin LG, et al. Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf 2003;26:421-38.28995 - Invirase (saquinavir) package insert. South San Francisco, CA: Genentech Inc.; 2020 Sept.29012 - Lexiva (fosamprenavir calcium) package insert. Research Triangle Park, NC: ViiV Healthcare; 2019 Mar29036 - Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism. Clin Pharmacokinet 2000;38:111-180.29087 - Dahan A, Altman H. Food-drug interaction: grapefruit juice augments drug bioavailability-mechanism, extent, and relevance. Eur J Clin Nutr 2004;58:1-9.29210 - Mycobutin (rifabutin) package insert. New York, NY: Pharmacia and Upjohn, Co.; 2021 Sep.29624 - Park JY, Kim KA, Kim SL. Chloramphenicol is a potent inhibitor of cytochrome P450 isoforms CYP2C19 and CYP3A4 in human liver microsomes. Antimicrob Agents Chemother 2003;47:3464-9.29702 - Covera-HS (verapamil hydrochloride tablets) package insert. New York, NY: Pfizer Inc.; 2011 Oct.29812 - Burman WJ, Gallicano K, Peloquin C. Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials. Clin Pharmacokinet. 2001;40:327-41.30117 - McLellan RA, Drobitch RK, Monshouwer M, Renton KW. Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human. Drug Metab Dispos 1996;24:1134-8.30676 - Emend (aprepitant oral products) package insert. Whitehouse Station, NJ: Merck & Co.,Inc.; 2019 Nov.31320 - Aptivus (tipranavir) package insert. Ridgefield, CT: Boehringer Ingelheim; 2020 Jun.31764 - Vaprisol (conivaptan hydrochloride injection) package insert. Deerfield, IL: Baxter Healthcare Corporation; 2016 Oct.32432 - Prezista (darunavir) package insert. Horsham, PA: Janssen Products, LP; 2023 Mar.32723 - Noxafil (posaconazole) package insert. Whitehouse Station, NJ: Merck & Co. Inc.: 2022 Jan.33557 - Tasigna (nilotinib) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2015 Oct.33718 - Intelence (etravirine) package insert. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2019 July.34329 - Eberl S, Renner B, Neubert A, et al. Role of p-glycoprotein inhibition for drug interactions: evidence from in vitro and pharmacoepidemiological studies. Clin Pharmacokinet 2007;46:1039-49.34375 - Ejendal KFK, Hrycyna CA. Differential sensitivities of the human ATP-binding cassette transporters ABCG2 and P-glycoprotein to cyclosporin A. Mol Pharmacol 2005;67:902-1134447 - Niwa T, Shiraga T, Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull. 2005;28:1805-1808.34455 - Yasuda K, Ranade A, Venkataramanan R, et al. A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos 2008;36:1689-97.34456 - Lang CC, Jamal SK, Mohamed Z, et al. Evidence of an interaction between nifedipine and nafcillin in humans. Br J Clin Pharmacol 2003;55:588-90.34464 - Wexler D, Courtney R, Richards W, et al. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004;21:645-53.34465 - Sansone-Parsons A, Krishna G, Simon J, et al. Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother 2007;51:495-502.34494 - Cornwell M, Pastan I, Gottesman M. Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem 1987;262:2166-70.34514 - Mahon FX, Belloc F, Lagarde V, et al. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood 2003;101:2368-2373.34549 - Reinach B, de Sousa G, Dostert P, et al. Comparative effects of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes. Chem Biol Interact 1999;121:37-48.34550 - Kuper JI, DAprile M. Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet 2000;39:203-14.34557 - Lee CG, Gottesman MM, Cardarelli CO. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 1998;37:3594-601.34558 - Storch CH, Theile D, Lindenmaier H, et al. Comparison of inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol 2007;73:1573-81.34559 - Choo EF, Leake B, Wandel C, et al. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 2000;28:655-60.34695 - Zhou SF. Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 2008;9:310-22.34717 - Konishi H, Takenaka A, Minouchi T, et al. Impairment of CYP3A4 capacity in patients receiving danazol therapy: examination on oxidative cortisol metabolism. Horm Metab Res 2001;33:628-30.34768 - Lang J, De Villaine JF, Touraine J. Cyclosporine (cyclosporin A) pharmacokinetics in renal transplant patients receiving ciprofloxacin. Am J Med 1989;87:82S-5S.34769 - Haaz MC, Rivory L, Riche C, et al. Metabolism of irinotecan (CPT-11) by human hepatic microsomes: participation of cytochrome P-450 3A and drug interactions. Cancer Res 1998;58:468-72.34772 - Hoey LL, Lake KD. Does ciprofloxacin interact with cyclosporine? Ann Pharmacother 1994;28:93-6.34773 - Van Buren DH, Koestner J, Adedoyin A, et al. Effect of ciprofloxacin on cyclosporine pharmacokinetics. Transplantation 1990;50:888-9.36101 - Multaq (dronedarone) package insert. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; 2023 Oct.39863 - Barry M, Mulcahy F, Merry C, et al. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 1999;36:289-304.39864 - Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir, and indinavir. Br J Clin Pharmacol 1997;44:190-194.40025 - Verelan PM (verapamil hydrochloride extended-release capsules) package insert. Gainesville GA: Recro Technology LLC;2019 Oct.40027 - Emend (fosaprepitant dimeglumine injection) package insert. Whitehouse Station, NJ: Merck & Co.,Inc.; 2022 May.40233 - Sporanox (itraconazole) oral solution package insert. Titusville, NJ: Janssen Pharmaceuticals, Inc.; 2024 Feb.41237 - Tegretol (carbamazepine) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2023 Sep.41243 - Provigil (modafinil) package insert. Frazer, PA: Cephalon; 2015 Jan.41911 - Brevital (methohexital) package insert. Chestnut Ridge, NY: Par Pharmaceutical; 2020 Oct.41934 - Lysodren (mitotane) package insert. Sermoneta, Italy: Corden Pharma Latina S.p.A.; 2024 Jan.45458 - Xalkori (crizotinib) capsules and pellets package insert. New York, NY: Pfizer Labs; 2023 Sept.47165 - Norvir (ritonavir tablets, solution, and powder) package insert. North Chicago, IL: AbbVie Inc; 2022 Dec.47184 - Fluvoxamine tablets package insert. Baudette, MN: ANI Pharmaceuticals, Inc.; 2023 Aug.48697 - Korlym (mifepristone) tablet package insert. Menlo Park, CA: Corcept Therapeutics; 2019 Nov.49229 - Amytal (amobarbital sodium) package insert. Bridgewater, NJ: Bausch Health US, LLC; 2020 Jul.49352 - Seconal (secobarbital sodium) capsules package insert. Jacksonville, Fl: Ranbaxy Pharmaceuticals, Inc.; 2008 Sept.51727 - Xtandi (enzalutamide) capsule and tablet package insert. Northbrook, IL:Astellas Pharma US, Inc.; 2023 Nov.54631 - Isoherranen N, Lutz JD, Chung SP, et al. Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data. Chem Res Toxicol 2012; 19:2285-2300.54632 - Hiemke C, Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000;85:11-28.54634 - Owen JR, Nemeroff CB. New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine. Depress Anxiety 1998;7:24-32.54713 - VFEND (voriconazole) injection package insert. New York, NY: Pfizer Inc; 2014 Sept.54802 - Tafinlar (dabrafenib) capsules package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2023 Aug.55436 - Patsalos PN, Berry DJ, Bourgeois BF. Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008;49:1239-1276.55768 - Cardizem (diltiazem tablets) package insert. Bridgewater, NJ: Bridgewater, NJ: Bausch Health US, LLC; 2020 Jun.56436 - Aptiom (eslicarbazepine acetate) package insert. Marlborough, MA: Sunovion Pharmaceuticals Inc.; 2019 Mar.56579 - Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Updated Mar 10, 2020. Retrieved from the World Wide Web at www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm57036 - Brodie MJ, Mintzer S, Pack AM, et al. Enzyme induction with antiepileptic drugs: cause for concern? Epilepsia 2013;54:11-27.57046 - Perucca E, Hedges A, Makki KA, et al. A comparative study of the relative enzyme inducing properties of anticonvulsant drugs in epileptic patients. Br J Clin Pharmacol 1984;18:401-10.57048 - Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers. Retrieved from the World Wide Web December 27, 2013. http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.htm#major57080 - de Leon J, Santoro V, D'Arrigo C, et al. Interactions between antiepileptics and second generation antipsychotics. Expert Opin Drug Metab Toxicol 2012;8:311-34.57094 - Zykadia (ceritinib) package insert. Indianapolis, IN: Novartis; 2021 Oct.57105 - Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 1996;49:311-318.57202 - Zhou S, Chan E, Pan S, et al. Pharmacokinetic interactions of drugs with St John's wort. J Psychopharmacol 2004;18:262-76.57675 - Zydelig (idelalisib) tablet package insert. Foster City, CA:Gilead Sciences, Inc.; 2022 Feb.57852 - Dostalek M, Pistovcakova J, Jurica J, et al. The effect of St John's wort (hypericum perforatum) on cytochrome p450 1a2 activity in perfused rat liver. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2011;155:253-7.58000 - Tybost (cobicistat) package insert. Foster City, CA: Gilead Sciences, Inc; 2021 Sept.58104 - Girennavar B, Jayaprakasha GK, and Patil BS. Potent inhibition of human cytochrome P450 3A4, 2D6, and 2C9 isoenzymes by grapefruit juice and its furocoumarins. Journal of Food Science. 2007;72(8):C417-C421.58171 - Akynzeo (fosnetupitant; palonosetron injection and netupitant; palonosetron capsules) package insert. Lugano, Switzerland: Helsinn Healthcare; 2023 February.58662 - Lynparza (olaparib) tablets package insert. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2023 Nov.58770 - Gleevec (imatinib mesylate) tablet package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2022 Mar.59042 - Cresemba (isavuconazonium) package insert. Northbrook, IL: Astellas Pharma US, Inc; 2023 Dec.59747 - Targretin (bexarotene) capsules package insert. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2013 May.59759 - Tempestilli M, Gentilotti E, Tommasi C, et al. Determination of P-glycoprotein surface expression and functional ability after in vitro treatment with darunavir or raltegravir in lymphocytes of healthy donors. Int Immunopharmacol 2013;16:492-497.59891 - Orkambi (lumacaftor; ivacaftor) tablet package insert. Boston, MA: Vertex Pharmaceuticals, Inc. 2023 August60092 - Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014; 58: e44-100.60871 - Vaxchora (Cholera Vaccine, live, oral) package insert. Redwood City, CA: Emergent Travel Health Inc.; 2022 Dec.61816 - Kisqali (ribociclib) tablets package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2023 Aug.62611 - Prevymis (letermovir) package insert. Rahway, NJ: Merck Sharp and Dohme, LLC.; 2023 Aug.62874 - Erleada (apalutamide) tablets package insert. Horsham, PA: Janssen Products, LP; 2023 Dec.63317 - Braftovi (encorafenib) capsules package insert. Boulder, CO: Array BioPharma Inc.; 2023 Oct.63387 - Orilissa (elagolix) tablets package insert. North Chicago, IL: AbbVie Inc.; 2023 Jun.63571 - Copiktra (duvelisib) capsules package insert. Las Vegas, NV: Secura Bio, Inc.; 2021 Dec.63732 - Lorbrena (lorlatinib) tablets package insert. New York, NY: Pfizer Labs; 2021 March.64100 - Dengvaxia (dengue tetravalent vaccine, live) package insert. Swiftwater, PA: Sanofi Pasteur Inc.; 2023 August.64535 - Turalio (pexidartinib) capsules package insert. Basking Ridge, NJ: Daiichi Sankyo, Inc.; 2023 Nov.64568 - Inrebic (fedratinib) capsules package insert. Summit, NJ: Celgene Corporation; 2021 Dec.64576 - Xenleta (lefamulin) package insert. Dublin, Ireland: Nabriva Therapeutics US, Inc.; 2021 Mar.64768 - Xcorpi (cenobamate) tablets package insert. Paramus, NJ: SK Life Science, Inc.; 2024 Jan.64778 - Oxbryta (voxelotor) tablets package insert. South San Francisco, CA: Global Blood Therapeutics, Inc.; 2023 Aug.65107 - Kroger A, Bahta L, Hunter P. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP).Available on the world wide web at https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf. Revised April 27, 2022. Accessed on July 14, 2022.65295 - Tukysa (tucatinib) tablets package insert. Bothell, WA: Seattle Genetics, Inc.; 2023 Jan65685 - Dooley KE, Bliven-Sizemore EE, Weiner M, et al. Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers. Clin Pharmacol Ther 2012; 91:566080 - Food and Drug Administration (FDA). Fact Sheet for Healthcare Providers Administering Vaccine: Emergency Use Authorization (EUA) of Pfizer-BioNTech COVID-19 Vaccine to Prevent Coronavirus Disease 2019 (COVID-19) for 12 years and older. Purple cap and purple border. Retrieved November 22, 2022.66129 - Zokinvy (lonafarnib) capsules package insert. Palo Alto, CA: Eiger BioPharmaceuticals, Inc.; 2020 Nov.66159 - Orladeyo (berotralstat) package insert. Durham, NC; BioCryst Pharmaceuticals, Inc.: 2023 Nov.66700 - Lumakras (sotorasib) tablet package insert. Thousand Oaks, CA: Amgen, Inc.; 2023 Apr.67543 - Camzyos (mavacamten) package insert. Princeton, NJ: Bristol-Myers Squibb; 2023 Jun.68325 - Krazati (adagrasib) tablets package insert. San Diego, CA: Mirati Therapeutics, Inc.; 2022 Dec.68383 - Sunlenca (lenacapavir) package insert. Foster City, CA: Gilead Science, Inc.; 2022 Dec.69127 - Litfulo (ritlecitinib) package insert. New York, NY: Pfizer Inc.; 2023 Jun69884 - Augtyro (repotrectinib) capsules package insert. Princeton, NJ: Bristol-Meyers Squibb Company; 2023 Nov.69917 - Ogsiveo (nirogacestat) tablets package insert. Stamford, CT: SpringWorks Therapeutics, Inc.; 2023 Nov.

      Monitoring Parameters

      • CBC with differential
      • pregnancy testing

      US Drug Names

      • Lynparza
      ;